Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

[1]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[2]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[4]  R. Stahel,et al.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  K. Krejcy,et al.  Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[7]  Elisa Giovannetti,et al.  Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non–Small-Cell Lung Cancer Cells , 2005, Molecular Pharmacology.

[8]  R M Schultz,et al.  LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. , 1997, Cancer research.

[9]  D. Cox,et al.  Analysis of Binary Data (2nd ed.). , 1990 .

[10]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[12]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Ian Diamond,et al.  Analysis of Binary Data. 2nd Edn. , 1990 .

[14]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[15]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[16]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[18]  T. Boulikas,et al.  Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). , 2004, Oncology reports.

[19]  R. Ramlau,et al.  FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) , 2008 .

[20]  E. Perez,et al.  Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). , 2008, Lung cancer.

[21]  Y. Soon,et al.  Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Giaccone,et al.  SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  V. Miller,et al.  A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  David R. Cox.  The analysis of binary data , 1970 .

[25]  H. Wakelee,et al.  Optimizing first-line treatment options for patients with advanced NSCLC. , 2005, The Oncologist.

[26]  N. Hanna.  Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial , 2008 .

[27]  M. Kris,et al.  Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale , 1994, Cancer.

[28]  Martin Marciniak,et al.  Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Hickish,et al.  Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Socinski,et al.  Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. , 2005, Lung cancer.

[31]  R. Ramlau,et al.  Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study , 2008 .

[32]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[33]  B. Milleron,et al.  Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[34]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Stahel,et al.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[37]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[38]  Michael J Schell,et al.  Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Tudor Ciuleanu,et al.  Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. , 2006, Lung cancer.

[40]  David E Morris,et al.  Chemotherapeutic management of stage IV non-small cell lung cancer. , 2003, Chest.

[41]  V. Miller,et al.  A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.